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Insulin use and Excess Fracture Risk 
in Patients with Type 2 Diabetes: 
A Propensity-Matched cohort 
analysis
Eladio Losada-Grande1,2, Samuel Hawley3, Berta Soldevila4,5, Daniel Martinez-Laguna6,8, 
Xavier Nogues7,8, Adolfo Diez-Perez7,8, Manel Puig-Domingo1,4,5, Dídac Mauricio4,5 & Daniel 
Prieto-Alhambra3,6,8
Despite normal to high bone mineral density, patients with type 2 diabetes (T2DM) have an increased 
fracture risk. T2DM medications could partially account for this excess risk. The aim of this study was to 
assess the association between insulin use and bone fracture risk in T2DM patients. A population-based 
matched cohort study based on a primary care records database validated for research use (Catalonia, 
Spain) was performed. Propensity score (PS) for insulin use was calculated using logistic regression 
including predefined predictors of fractures. A total of 2,979 insulin users and 14,895 non-users were 
observed for a median of 1.42 and 4.58 years respectively. Major fracture rates were 11.2/1,000 
person-years for insulin users, compared with 8.3/1,000 among non-users. Matched models confirmed 
a significant association, with an adjusted subhazard ratio (adj SHR) of 1.38 [95% CI 1.06 to 1.80] for 
major fractures. No differences between types of insulin or different regimens were found. Estimated 
number needed to harm (fracture) was 82 (95% CI 32 to 416). Insulin use appears to be associated with a 
38% excess fracture risk among T2DM patients in the early stages of the disease. Fracture risk should be 
included among the considerations to initiate insulin treatment.
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of bone fractures1–13 despite a normal 
to high bone mineral density (BMD) compared with non-diabetic subjects10, 14–17. Although the mechanisms 
underlying this observed excess fracture risk among T2DM patients remain unclear, some evidence indicates 
that fragility fractures in T2DM patients may be explained by the presence of impaired structural properties that 
compromise bone quality and ultimately lead to bone fragility18, 19.
Risk factors associated with fracture risk in T2DM include duration of disease7, 9, 14, diabetic complications 
[impaired vision1, 14, peripheral neuropathy20, orthostatic hypotension21, etc.], episodes of hypoglycaemia22, 
increased risk of falling20, 22–24, inadequate glycaemic control25, and some antidiabetic medications that appear to 
affect bone metabolism, such as glitazones26, 27. Conversely, data on the impact of insulin treatment on fractures 
in T2DM are scarce and remain controversial, with some4, 6–9, 13 but not all1, 28 studies showing an increased risk 
of fracture. Most of the previous cohorts had no information on date of diagnosis or of insulin therapy initiation, 
making it difficult for researchers to accurately estimate attributable excess risk1, 4, 6–9, 13.
The increased risk observed in most observational studies has also been attributed to disease severity as most 
of the previously analysed cohorts lacked information on glycated haemoglobin (HbA1c), a key parameter to 
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Unmatched Participants Matched Participants
Non-users 
of Insulin 
(N = 50,626)
Users of Insulin 
(N = 3,227)
P-value**
Non-users 
of Insulin 
(N = 14,895)
Users of Insulin 
(N = 2,979)
P-value**N % N % N % N %
Demographic risk factors
Sex, male 28,323 60 1,844 57.1 0.18 8,411 56.5 1,678 56.3 0.89
Age, years
 Mean (SD) 63.7 (11.2) 61.2 (11.9) <0.001 61.7 (11.9) 61.8 (11.9) 0.76
Body Mass Index §∧
 Mean (SD) 31.1 (5.2) 30.8 (5.9) 0.002 31.0 (5.6) 30.8 (5.8) 0.097
Socio-economic status ±
 Quintile1 (−1.83 to 0.03) 9,379 18.5 581 18.0 2,654 17.8 532 17.9
 Quintile 2 (0.03 to 0.50) 9,387 18.5 557 17.3 2,589 17.4 518 17.4
 Quintile 3 (0.50 to 0.94) 9,368 18.5 582 18.0 2,762 18.5 536 18.0
 Quintile 4 (0.94 to 1.52) 9,347 18.5 541 16.8 2,561 17.2 513 17.2
 Quintile 5 (1.52 to 5.28) 9,238 18.3 664 20.6 2,975 20.0 599 20.1
    Unknown 3,907 7.7 302 9.4 <0.001 1,354 9.1 281 9.4 0.98
Smoking
 Never 18,824 37.2 1,005 31.1 4,760 32.0 938 31.5
 Ex-smoker 6,914 13.7 551 17.1 2,438 16.4 485 16.3
 Current 7,737 15.3 441 13.7 2,035 13.7 416 14.0
 Unknown 17,151 33.9 1,230 38.1 <0.001 5,662 38 1,140 38.3 0.94
Drinking
 Never 21,325 42.1 1,149 35.6 5,450 36.6 1,128 37.9
 Moderate 10,777 21.3 341 10.6 1,663 11.2 337 11.3
 Severe 1,458 2.9 66 2.1 329 2.2 63 2.1
 Unknown 17,066 33.7 1,671 34.8 <0.001 7,453 50.0 1,451 48.7 0.55
Conditions affecting fracture risk
Fracture 1,053 2.1 57 1.8 0.22 257 1.7 54 1.8 0.74
Stroke 1,561 3.1 113 3.5 0.18 508 3.4 108 3.6 0.56
Myocardial infarction 1,463 2.9 95 2.9 0.86 409 2.8 88 3.0 0.53
Falls 456 0.9 16 0.5 0.017 76 0.5 16 0.5 0.85
Conditions related to diabetes
eGFR
   <60 6,043 11.9 409 12.7 1,885 12.7 375 12.6
   Unknown 8,326 16.5 834 25.8 <0.001 3,842 25.8 767 25.8 0.99
Neuropathy 692 1.4 181 5.6 <0.001 530 3.6 108 3.6 0.22
HbA1c±∧
 Quintile 1 (3.5 to 5.7) 9,285 18.3 320 9.9 1,564 10.5 318 10.7
 Quintile 2 (5.8 to 6.2) 9,270 18.3 267 8.3 1,340 9.0 267 9.0
 Quintile 3 (6.3 to 6.6) 7,489 14.8 247 7.7 1,235 8.3 243 8.2
 Quintile 4 (6.6 to 7.3) 7,328 14.5 355 11.0 1,738 11.7 348 11.7
 Quintile 5 (7.4 to 19.1) 7,147 14.1 1,046 32.4 4,285 28.8 881 29.6
   Unknown 10,107 20.0 992 30.7 <0.001 4,733 31.8 922 31.0 0.94
Medications associated with fracture risk
Diuretics 6,727 13.3 351 10.9 <0.001 1,743 11.7 330 11.1 0.33
Antihypertensive 23,035 45.5 1,729 53.6 <0.001 6,488 43.6 1,610 54.0 <0.001
Diuretic plus antihypertensive 12,732 25.2 725 22.5 0.001 3,436 23.1 669 22.5 0.47
Steroids 3,163 6.3 346 10.7 <0.001 1,461 9.8 322 10.8 0.096
Medications associated with osteoporosis treatment
Bisphosphonates 2,207 4.4 130 4.0 0.37 565 3.8 122 4.1 0.43
SERMs 295 0.6 14 0.4 0.27 59 0.4 13 0.44 0.75
Teriparatide 44 0.1 1 <0.1 0.51 4 <0.1 1 <0.1 0.84
Medications for diabetes treatment
Metformin*** 16,690 33.0 901 27.9 <0.001 4,203 28.2 839 28.2 0.95
Sulphonylureas 1,691 3.3 272 8.4 <0.001 1,005 6.8 215 7.2 0.35
Meglitinides 227 0.5 47 1.5 <0.001 153 1.0 41 1.4 0.093
Continued
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assess T2DM metabolic control1, 4–9, 14. However, insulin therapy could affect fracture risk in several ways: it is 
related to an increased risk of hypoglycaemia which may induce falls and, in some experimental models, it has 
been associated with a disregulation of osteoclastogenesis29, 30. Nonetheless, no direct negative effect of insulin 
therapy on bone has yet been directly demonstrated in randomised controlled trials.
In the present study, we analysed detailed clinical information from a large cohort of newly diagnosed T2DM 
patients to investigate an association between insulin use and fracture risk in these subjects.
Results
We identified 53,853 patients newly diagnosed with T2DM who fulfilled inclusion and exclusion criteria in the 
Information System for Research Development in Primary Care database (Catalan acronym, SIDIAP) between 
2006 and 2013. Of these, 3,227 initiated insulin therapy (with ≥2 months persistence) and 50,626 (94%) never 
used insulin throughout the study period. Baseline characteristics differed significantly between insulin users and 
non-users in terms of: age, body mass index (BMI), socio-economic status (SES), smoking status, alcohol intake, 
previous falls, glomerular filtration rate (GFR), neuropathy, HbA1c level, use of medications related with fracture 
risk (diuretics, antihypertensives, diuretics plus antihypertensives, and steroids), use of some antidiabetic medica-
tions (metformin, sulphonylureas, and meglitinides), and index year of diagnosis. Most of these differences were 
attenuated after propensity score (PS) matching: 2,979/3,227 (92.3%) insulin users were matched to 14,895/50,626 
(29.4%) non-users of similar characteristics. Differences (P < 0.1) remained post-matching only in terms of BMI 
and use of certain medications (antihypertensives, steroids, and meglitinides) (Table 1).
The included participants were then observed for a median inter-quartile range (IQR) of 4.84 (3.09 to 6.44) 
years, totalling 81,761 person-years (PYs). At least one major fracture occurred in 60/2979 insulin users (in ~5400 
PYs) and 631/14,895 PS-matched non-users (in ~76,000 PYs), an equivalent to incidence rates of 11.2/1,000 (95% 
CI 8.7 to 14.4) and 8.3/1,000 PY (95% CI 7.6 to 8.9), respectively.
Survival models confirmed an association between insulin use and fracture risk in the matched cohorts [unad-
justed subhazard ratio (SHR) and (95% CI) 1.43 (1.10 to 1.86)], which remained unchanged after further adjust-
ment for BMI, steroid use, meglitinides, and anti-hypertensive drugs (i.e. the variables that remained imbalanced 
after PS matching [P < 0.1]): adjusted (adj) SHR 1.38 (1.06 to 1.80) (Table 2). Fracture cumulative incidence 
function plots stratified by insulin use are depicted in Fig. 1.
At 5 years, the estimated number needed to harm (NNH) - i.e., the number of patients treated with insulin for 
5 years needed to cause 1 major fracture – was 82 (95% CI 32 to 416).
Unmatched Participants Matched Participants
Non-users 
of Insulin 
(N = 50,626)
Users of Insulin 
(N = 3,227)
P-value**
Non-users 
of Insulin 
(N = 14,895)
Users of Insulin 
(N = 2,979)
P-value**N % N % N % N %
GLP-1 analogues 13 <0.1 1 <0.1 0.86 5 <0.1 1 <0.1 1
DPP4-i 129 0.25 13 0.4 0.11 60 0.4 13 0.44 0.79
Other (non-insulin) meds 73 0.14 19 0.6 <0.001 54 0.36 15 0.5 0.26
Index year****
2006 6,276 12.4 823 25.5 3,453 23.2 627 21.1
2007 6,394 12.6 649 20.1 2,977 20.0 606 20.3
2008 6,503 12.9 550 17.0 2,618 17.6 541 18.2
2009 7,598 15.0 453 14.0 2,211 14.8 453 15.2
2010 8,355 16.5 354 11.0 1,723 11.6 354 11.9
2011 7,674 15.2 235 7.3 1,147 7.7 235 7.9
2012 7,826 15.5 163 5.1 <0.001 766 5.1 163 5.5 0.35
Table 1. Baseline characteristics of patients with incident T2DM stratified by insulin use vs non-insulin 
use during follow-up. §Although presented here as continuous; BMI and age were entered into PS model as 
categorical variables incorporating a missing category. **P-values are reported for chi-square (categorical 
variables) and t-test (continuous variables), comparing the distribution of baseline characteristics between 
insulin users and non-users. ***Metformin counted in year prior to index date (other comedications only 
counted in prior month). ****Index date defined as 01/01/2006 or date of T2DM diagnosis (if after 01/01/2006) 
or date of enrolment with GP (if after T2DM diagnosis). This was ‘baseline’, and a time-varying covariates 
model was used, splitting follow-up time at start of insulin use. ∧Missingness: Non-matched [BMI = 16.0% 
(non-insulin user), 23.9% (insulin user); HbA1c = 19.7% (non-insulin user), 30.7% (insulin user)]; matched 
[BMI = 23.8% (non-insulin user), 23.4% (insulin user); HbA1c = 31.8% (non-insulin user), 31.0% (non-
insulin user). ±Mean values within each quintile for the propensity score matched cohorts for socio-economic 
status: Q1 = −0.14, Q2 = 0.28, Q3 = 0.73, Q4 = 1.21, Q5 = 2.25 (non-user) and Q1 = −0.38, Q2 = 0.23, 
Q3 = 0.74, Q4 = 1.20, Q5 = 2.28; for HbA1c: Q1 = 5.32, Q2 = 6.01, Q3 = 6.44, Q4 = 6.95, Q5 = 8.88 (non-user) 
and Q1 = 5.27, Q2 = 6.00, Q3 = 6.45, Q4 = 9.97, Q5 = 9.66 (user). Abbreviations: Type 2 diabetes mellitus 
(T2DM), estimated glomerular filtration rate (eGFR), haemoglobin A1C (HbA1c), selective oestrogen receptor 
modulators (SERMs), glucagon-like peptide −1 (GLP-1), dipeptidyl peptidase-4 inhibitors (DPP4-i).
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Models assessing the association between insulin therapy adherence and fracture risk showed a dose-response 
gradient for the first three quartiles of medication possession ratio (MPR): adj SHR 2.58 (1.56 to 4.26) for those 
in the third quartile, compared with an adj SHR of 0.92 (0.50 to 1.71) for low-dose (first quartile) insulin users 
(Table 3). In a separate analysis to study the effect of different insulin types, 34 patients fractured while taking 
long-acting human insulin, compared to 12 fractures in patients treated with long-acting analogues (adj SHR 1.02 
[0.52 to 1.99]); and 38 fractures were seen in users of long-acting compared to 5 users of mixed insulin regimens 
(short and fast-acting combination) (SHR 0.76 [0.30 to 1.96]) (data not shown).
A number of sensitivity analyses were conducted to confirm the robustness of our findings. Firstly, we studied 
interactions with sex, age, and HBA1c levels, obtaining results that were similar to those in the main analysis. 
Results remained also unchanged after excluding early insulin users (and matched non-users) who initiated ther-
apy within 6 months after T2DM diagnosis [adjusted SHR 2.00 (1.45 to 2.77)]; similarly, reclassifying insulin use 
in the first two months of treatment as non-user time obtained similar findings to our main analysis [adj SHR 
1.28 (0.96 to 1.71)].
In an additional sensitivity analysis, results were unchanged when multiple imputation was used to account 
for missing BMI and HbA1c values (Supplementary Table 1). Also, further adjustment for median HbA1c over 
time after T2DM diagnosis did not modify the observed association (Supplementary Table 2). Finally, we con-
ducted an analysis where insulin dosage (in the form of MPR) was corrected for BMI and stratified by gender. 
This confirmed our previous findings both in men (Supplementary Table 3) and women (Supplementary Table 4).
Discussion
We report a significant (38%) excess risk of major osteoporotic fractures among recently diagnosed T2DM 
patients exposed to insulin therapy, compared with PS-matched insulin non-users with T2DM. This association 
remained unmodified after adjusting for imbalanced variables. Assuming a causal relationship and considering 
the estimated NNH, approximately 82 recently diagnosed T2DM would need to be treated with insulin to pro-
duce an attributable major fracture within 5 years. No differences were found in terms of excess fracture risk when 
users of different types of insulin (human vs. analogues, long-acting vs. long plus short-acting) were compared.
In general, our excess risk results were consistent with most published observational studies in which insulin 
therapy has been related to a higher risk of hip and major bone fractures1, 13. However, most of these studies inves-
tigated only subgroups of the population, specifically the elderly7–9 or postmenopausal women4–6, 9 and some did 
not differentiate between type 1 diabetes mellitus (T1DM) and T2DM7, 13. Additionally, most studies involved 
patients with pre-existing T2DM6–9, 11, 13 or did not report on disease duration6. Similarly, some previous reports 
lacked information on disease severity, as defined by glycaemic control6–9, 11, 13, and nearly all of the studies lacked 
information or did not adjust for the date of onset of insulin therapy, the type of insulin, or the regimen/dose 
used6–9, 11–13.
Conflicting data have been obtained when the effect of anti-diabetic treatments (including insulin) on bone 
fracture was studied as a primary endpoint. In a nationwide, population-based, case-control study in Denmark, 
Non-users of insulin (14,895) Users of insulin (2,979)
SHR adjSHRN
Median follow-up 
(years) (IQR) Rate (per 1000 PYs) N
Median follow- up 
(years) (IQR) Rate (per 1000 PYs)
631 4.58 (2.60–6.32) 8.26 (7.64–8.93) 60 1.42 (0.67–2.67) 11.19 (8.69–14.42) 1.43 (1.10–1.86) 1.38 (1.06–1.80)
Table 2. Fracture incidence among matched users of any insulin (N = 2,979) and non-users of insulin 
(N = 14,895). Only the first continuous insulin use considered (switching types was accounted for), then 
censored. All analyses include incident insulin use as a time-dependent covariate. Analyses are PS matched 
at a 5:1 ratio of non-users to users. Adjusted analyses control for outstanding confounders (P < 0.1), i.e. BMI, 
steroids, meglitinides, and anti-hypertensive therapy. Abbreviations: N (number of fractures), Interquartile 
range (IQR), person-years (PYs), subhazard ratio (SHR), adjusted (adj).
MPR Non-users of insulin (14,900) Users of insulin (2,980)
SHR adj SHRQuartile Median (IQR) N
Median 
follow-up 
(years)
Rate (per 
1000 PYs) N
Median 
follow-up 
(years)
Rate (per 
1000 PYs)
1 21 (21–31) 235 4.5 8.8 11 0.8 7.8 0.94 (0.51–1.73) 0.92 (0.50–1.71)
2 41 (41–51) 147 4.6 7.1 17 1.3 12.6 1.85 (1.12–3.04) 1.85 (1.12–3.05)
3 62 (62–72) 97 4.6 7.2 18 1.7 17.9 2.58 (1.56–4.26) 2.58 (1.56–4.26)
4 103 (84–123) 151 4.7 9.5 10 1.9 7.5 0.82 (0.43–1.57) 0.84 (0.45–1.60)
Table 3. Fracture incidence among users of any insulin (N = 2,980) vs matched non-users (N = 24,900), 
stratified by quartiles of insulin medication possession ratio (MPR) within first year of first insulin use. Only 
the first insulin use considered (i.e. switching types was not accounted for), then censored. All analyses include 
incident insulin use as a time dependent covariate. Analyses are PS matched, on a 5:1 ratio of non-users to users 
in a separate model from the main analysis. Adjusted analyses control for outstanding confounders (P < 0.1) 
and for propensity score. Abbreviations: N (number of fractures), Interquartile range (IQR), person-years (PYs), 
subhazard ratio (SHR), adjusted (adj).
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insulin therapy showed a non-significant trend towards a decreased risk of bone fracture after adjusting for mul-
tiple confounders11. In an Italian case-control study28, insulin use during at least 36 months in the previous 10 
years was not associated with fracture risk.
In our dataset, insulin use was associated with an increased risk of major osteoporotic fractures independent 
of T2DM disease duration, glycaemic control (disease severity), and other potential confounders. Therefore, our 
findings suggest that insulin therapy may have played a role in this excess risk rather than, as has been suggested 
by previous authors, acting as a surrogate of longer disease duration or severity31, 32.
Previous publications have indicated that insulin stimulates the regulation of osteoblast function, increas-
ing the proliferation and differentiation from mesenchymal stem cells (MSC) in both animal models and 
human studies33. In rodents, including insulin receptor substrate-1 (IRS-1) and IRS-2 knock-out mice and 
streptozotocin-induced diabetic mice, studies have shown severe osteopenia, decreased bone formation, and 
severe growth retardation, respectively34–36. In humans, data from young T1DM patients show more osteopenia 
and osteoporosis than in non-diabetic subjects37. In a 7-year follow-up study in young patients with T1DM, treat-
ment with intensive insulin therapy stabilized BMD and decreased bone resorption markers38.
In contrast to T1DM, where marked insulin deficiency is the pathogenetic substrate of hyperglycaemia, insu-
lin resistance with relative insulin deficiency results in different degrees of hyperinsulinemia during much of 
the natural history of T2DM. Additionally, it is well known that once insulin treatment is established, adequate 
levels of portal insulin are obtained at the expense of peripheral hyperinsulinemia, which may have an impact 
on various organs and tissues (e.g., bone). In vitro and in vivo models have shown a relationship between hyper-
insulinemia and alterations in bone resorption, as well as impaired bone formation via a negative regulation of 
osteoclastogenesis29, 30.
Long-acting human insulins are more closely related to symptomatic, overall, and nocturnal hypoglycaemias 
than are long-acting insulin analogues39. Short-acting insulins (basal-bolus or premixed insulin regimens) are 
most commonly used in more severe (less controlled) cases of T2DM, and are also associated with a higher risk 
of hypoglycaemia40. In our study, we did not find risk differences between users of different types of insulin. 
Participants taking higher doses of insulin had an increased fracture risk in a dose-response gradient for the 3 first 
quartiles; the absence of increased fractures in the fourth quartile is not concordant with the results in the other 
three quartiles. This finding raises additional questions about the reason why the insulin group has an increased 
rate of bone fractures. There are some plausible biological hypotheses. For instance, an increased number of 
hypoglycaemia readings was related with an increased risk of falls in the insulin group; however, it is possible that 
insulin therapy may exert its deleterious effects on bone tissue only at certain concentrations and/or that insulin 
at higher concentrations influences other intermediate factors affecting bone metabolism29, 30. The observational 
design and the aims of our study are not adequate to provide definitive answer to this key question.
The main limitation of our study was the lack of validation of each individual fracture. However, previous val-
idation of fractures as recorded in SIDIAP has shown the database to be very precise (>95% accuracy for all frac-
ture sites), compared with prospective cohort and hospital admissions data41. A recent validation study showed 
that the proposed list of ICD-10 codes is useful in distinguishing fragility (i.e., osteoporotic) fracture from high 
energy-induced fractures, with >90% of the coded hip fractures occurring after minimal trauma42.
The definition of insulin exposure used in the present study was based on pharmacy dispensation data. It is 
therefore reasonable to assert that patients used most of the dispensed doses; however, this could not be verified.
Another limitation was that the date of recorded T2DM diagnosis might not reflect the actual time of disease 
onset, which could have occurred months before a diagnosis was made and recorded.
One unresolved issue is the potential for residual confounding secondary to unobserved variables. Our data-
base lacks variables such as BMD status, calcium/vitamin D or use of medication that may impact fracture risk, 
such as antidepressants, sedatives, and antipsychotics. However, this is unlikely to be imbalanced between treat-
ment groups, as under current guidelines the indication for insulin therapy is based on T2DM metabolic control 
(such as HbA1c) and other parameters not including BMD or medications.
The misclassification of type 1 or low autoimmune diabetes of the adult (LADA diabetes) patients is also a 
potential limitation. Patients with T1DM or LADA improperly classified as T2DM require early insulin therapy 
Figure 1. Cumulative incidence function plot of bone fracture after type 2 diabetes mellitus diagnosis between 
non-insulin and insulin users accounting for time-varying exposure.
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initiation, which could explain the observed association with fracture risk. However, our sensitivity analysis 
excluding early insulin use (6 months post-T2DM diagnosis) did not support this explanation.
Finally, no pathophysiological information (circulating levels of insulin or other parameters potentially 
involved in bone health such as IGF-1, osteocalcin, and others) was available, nor were the number of hypogly-
caemic readings, falls, menopause status, or specific fracture site. These data would be interesting; however, this 
information is usually not available in primary care databases.
Our study also has several notable strengths. It is the largest cohort study available on the effect of insulin use 
on fracture risk. The inclusion of only incident T2DM cases enables a more accurate assessment of the association 
with insulin use by reducing the effect of differential times from T2DM onset. The SIDIAP database contains 
detailed information on glycaemic control (HbA1c levels), not been accounted for in most previous studies. 
Additionally, our study uses state-of-the-art analytical methods (i.e., PS calliper matching) to minimize con-
founding via indication. Finally, the innovative use of a Fine and Gray survival analysis allowed us to adjust for 
competing risk with differential death according to insulin use.
The quality of the data used in this investigation has been confirmed in recent studies showing the represent-
ativeness of the SIDIAP database for the Catalan population43–46.
In conclusion, insulin therapy is related to approximately 40% increase in the risk of major fracture, even in 
early stages of T2DM. Assuming this association is causal, the use of insulin for 5 years in 82 patients with T2DM 
would induce 1 major osteoporotic fracture. These results suggest that the risk of fracture associated with insulin 
use should be taken into account in the process of deciding on a treatment approach; a systematic evaluation of 
fracture risk factors may be needed in all T2DM patients prior to the initiation of insulin treatment. Further stud-
ies, especially randomised controlled trials where possible, are needed to confirm this association.
Research Design and Methods
Data collection. This was a population-based matched cohort study of 53,853 newly diagnosed T2DM par-
ticipants obtained from the SIDIAP database. SIDIAP contains primary care electronic medical records of a sam-
ple of patients in Catalonia (Northeast Spain), and includes a population of approximately 5 million patients (80% 
of the total population of Catalonia). Incorporated in the database, as part of routine practice, are the clinical and 
referral events registered by primary care administrative staff and health professionals (GPs and nurses), as well as 
demographic information, prescription and corresponding pharmacy invoicing data, specialist referrals, primary 
care laboratory test results, hospital admissions, and major patient outcomes.
We screened the SIDIAP database for patients who had an incident diagnosis of T2DM between 1 January 
2006 and 31 December 2012. Exclusion criteria were a T2DM diagnosis date (i) before 1 January 2006 (i.e., 
pre-existing cases), (ii) before the registration date with the primary care practice or (iii) during the final year of 
the study period. Also excluded were users of diabetic medication longer than one month before T2DM diag-
nosis (likely pre-existing diabetes), insulin users with less than 2 months’ persistence (possible prescription 
errors), patients with advanced chronic kidney failure [estimated glomerular filtration rate (eGFR) ≤15], and 
patients <40 years of age on the date of T2DM diagnosis (potentially misclassified T1DM). No specific data 
collection procedures were applied. The index date was defined as 1 January 2006 or date of T2DM diagnosis 
(if after 1/1/2006). As data collection proceeded, each insulin user was PS-matched to 5 non-users, using data 
pertaining to the moment of T2DM diagnosis. Each patient was followed up from the T2DM diagnosis date to 
the first of the following end points: study end date, end of insulin treatment, fracture event, date transferred out 
of the practice, or death.
Patient involvement. All data analysis was carried out in accordance with current and relevant guidelines 
and regulations. The study was approved by the Institut d´Investigació d´Atenció Primària Jordi Gol (IDIAP Jordi 
Gol). Active patient involvement activities and written informed consent were not required because all SIDIAP 
data were anonymized.
Outcomes. The study outcome was an incident major bone fracture sustained after T2DM diagnosis and 
during the study period 1/1/2006 to 31/12/2013. Fracture events at the following sites were included as major 
fractures in the analyses: hip, clinical spine, pelvis, tibia, multiple rib, proximal humerus, and wrist/forearm. All 
fracture events were ascertained from primary care and hospital data using previously validated lists of ICD-10 
codes29, 30.
Exposures. The main exposure of interest was exposure to insulin for the treatment of T2DM, compared 
with no exposure to insulin. In secondary analyses, the exposures were the use of human vs. analogue insulin, 
long-acting vs. long-acting plus short-acting insulin and any insulin use with a high (third and fourth quartiles) 
MPR, compared to low MPR (first and second quartiles).
Long-acting human insulin (NPH), long-acting insulin analogues (NPL, glargine, or detemir insulin), 
short-acting insulins (regular, aspart, lispro, and glulisine), and premixed insulins (NPH plus regular insulin 
70:30 or plus aspart insulin 30:70, 50:50, or 70:30; NPL plus lispro insulin 25:75 or 50:50) were considered.
Pharmacy dispensations of these medications were identified from the official regional reimbursement 
database (“Facturació de Farmàcia CatSalut” in Catalan) using national product codes, mapped to the WHO 
Anatomic Therapeutic Classification (ATC) codes and SIDIAP data. Treatment episodes were calculated as the 
time from the first to last insulin prescription, plus the number of daily-defined doses (DDDs as per the WHO 
ATC catalogue) purchased in the last prescription issued during the study period. For all comparisons, insulin use 
was defined as persisting two or more months.
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Confounders. Potential confounders of an insulin-fracture association were pre-defined based on clinical 
knowledge and a literature search for data pertaining to T2DM patients. These variables included age, gender, SES, 
calendar year of diagnosis, BMI, smoking status, and alcohol use. For BMI, smoking, and alcohol, only the value 
recorded nearest to T2DM diagnosis in the 5 years preceding the index date was used. We noted medications 
affecting fracture risk (steroids, diuretics, other anti-hypertensive drugs and mixed diuretics/anti-hypertensives) 
and osteoporosis treatment (parathyroid hormone, hormone replacement therapy, selective oestrogen recep-
tor modulators (SERMs), and bisphosphonates). These medications were considered potential confounders in 
the 6 months prior to the index date. We also considered previous conditions affecting fracture risk (stroke, 
myocardial infarction, falls, and previous history of fracture) and diabetic complications (polyneuropathy, renal 
failure), HbA1c levels were considered in two different ways. As current HbA1c, the most recent value prior to 
T2DM diagnosis, and median HbA1c, the average of values during the follow up. We considered T2DM medi-
cations taken in the month prior to the index date such as metformin, sulphonylureas, meglitinides, dipeptidyl 
peptidase-4 inhibitors (i-DPP4), glucagon-like peptide-1 analogues (GLP-1) and other non-insulin medication 
for diabetes (alpha glucosidase inhibitors and thiazolidinediones).
Statistical analysis. Due to the non-random allocation of insulin therapy, we calculated the PS for treat-
ment with insulin, which was defined as a patient’s conditional probability of exposure to insulin given observed 
prognostic characteristics. We used multivariable logistic regression models to derive the score, including a priori 
confounders in addition to significant predictors (p < 0.2) of the outcome. Incident exposure to insulin (yes/no) 
was used as the binary outcome.
Confounding factors included in the final PS were those identified a priori or as predictive of outcome and 
were included in the model. Missingness in the above variables was incorporated as a separate category.
Using the R matching package, we matched each insulin user to 5 non-users within a specified calliper width 
of 0.2 of the standard deviation of the logit of the PS. The PS matching between insulin users and non-users was 
performed at the point of the T2DM diagnosis. The incidence rate of major osteoporotic fracture was estimated 
for insulin users and matched non-users. The first episode of continuous use of insulin (taking into account the 
switching of different insulin types) was considered, with the cessation of treatment defined as the last dispen-
sation of insulin prior to a gap ≥6 months. Each patient was followed up from the diagnosis date of T2DM to 
the first of the following dates: end of study, end of insulin treatment, fracture event, transferred out, or death. A 
time-dependent covariate approach was taken, whereby follow-up for patients initiating insulin use after their 
diagnosis date for T2DM was split on the date of their first insulin dispensation to account for the switching of 
exposure status. In this manner, delayed users of insulin were considered non-users for the time period from their 
diagnosis date until their first dispensation date.
Univariable (matched) competing risk survival models (as proposed by Fine and Gray) were used, to account 
for the competing risk of death and to compare the time-to-fracture among insulin users vs. non-users47. The out-
put of these models was SHRs, which are estimates of the relative instantaneous probability of fracture conditional 
upon survival (i.e., subjects are not removed from the sample when competing risks occur). Schoenfeld residuals 
from Cox models were used to check the validity of the proportional hazards assumption. Multivariable models 
were used to adjust for any confounding factors from the final PS model that remained unbalanced between the 
insulin users and non-users.
To explore the possibility of a dose-response relationship between insulin and fracture risk, we repeated 
the main analysis according to quartile of MPR for first insulin use. Here, we only considered the first insulin 
medication (censored upon switching) and recalculated the PS score, so matching was not identical, as in the 
main analysis, and the numbers of patients and fractures reported differed slightly. Furthermore, main analyses 
were repeated after multiple imputation with chained equations was used to impute missing values for BMI and 
HbA1c.
Sensitivity analysis. We performed several sensitivity analyses to assess the robustness of our results using 
stratification and adjustment by PS. We studied the possible interactions of age, gender, and HbA1c levels in the 
primary outcome results by introducing multiplicative terms in the regression models. Insulin use was defined 
as patient retrieval of two months’ insulin prescription; to avoid immortal time bias, participants in the first two 
months of insulin treatment were considered as non-users (i.e., time-varying exposure) in a further sensitivity 
analysis48. To explore the potential impact of misclassification of T2DM on bone fracture, we also excluded the 
early insulin users (i.e., first 6 months after diagnosis), which permitted the exclusion of possible T1DM or LADA 
patients that may have been misclassified as T2DM.
A sensitivity analysis was also carried out to determine the impact of body mass on dose-effect, where the 
medication possession rate was divided by BMI and stratified by gender.
In a final sensitivity analysis, propensity-matched models were further adjusted for median HbA1c over follow 
up time.
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